Cagrilintide 5mg

Cagrilintide Research Topics:

1. 1. Promotes Significant Weight Management:

      In adults with overweight or obesity, weekly cagrilintide led to mean bodyweight management of 6.0–10.8% over 26 weeks—showing statistically superior results compared to placebo. [1]

   2. Well-Tolerated Safety Profile:

      Both as monotherapy and in combination with semaglutide, cagrilintide exhibited an acceptable safety and tolerability profile; the most common side effects were mild-to-moderate gastrointestinal symptoms. [3]

   3. Cardiac Safety Observed:

      A thorough QT (heart rhythm) study in healthy adults confirmed that cagrilintide does not prolong QTc intervals, indicating a lower risk of cardiac rhythm disturbances. [4]

Reference Citation:

1. 1. Lau DCW, Erichsen L, Francisco AM, et al. (2021). Once‑weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double‑blind, placebo‑controlled and active‑controlled, dose‑finding phase 2 trial. Lancet, 398(10317), 2160–2172.
   2. Frias JP, Deenadayalan S, Erichsen L, et al. (2023). Efficacy and safety of co‑administered once‑weekly cagrilintide 2.4 mg with once‑weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double‑blind, active‑controlled, phase 2 trial. Lancet, 402(10403), 720–730.
   3. Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021).
      Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. PubMed PMID: 33857449
   4. Gabe, M. B. N., Fuhr, R., Sinn, A., et al. (2024). Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity and Metabolism, 26(12), 5805–5811. PMID: 39279639